Company · Montreal, Quebec, Canada
Pharmascience Inc.
Everything this company holds in Health Canada’s product databases, as the company’s name is spelled there.
- Drug products (DIN)
- 1,373
- 674 authorized now
- Natural health products
- 107
- 63 active licences
- Medical device licences
- 0
- 0 active
- Notices of Compliance
- 1,224
Drug products
Authorized products first.
Showing 300 of 1,373 drug products. For the rest, search Health Canada’s database.
Natural health products
Active licences first, newest first.
Notices of Compliance
Newest first.
- PMS-LOXAPINEOctober 9, 2026 · NOC 38436 · New Drug Submission (NDS)
- PMS-DICLOFENACOctober 6, 2026 · NOC 38411 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-ROSUVASTATINOctober 1, 2026 · NOC 38393 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-METHADONE TABLETSSeptember 29, 2026 · NOC 38386 · Abbreviated New Drug Submission (ANDS)
- PMS-SACUBITRIL-VALSARTANSeptember 29, 2026 · NOC 38388 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-RUPATADINESeptember 25, 2026 · NOC 38367 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-BUSPIRONESeptember 24, 2026 · NOC 38361 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-LEVODOPA-CARBIDOPA CRSeptember 18, 2026 · NOC 38318 · Abbreviated New Drug Submission (ANDS)
- PMS-VALPROIC ACID; PMS-VALPROIC ACID E.C.September 4, 2026 · NOC 38262 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-METRONIDAZOLE GELAugust 14, 2026 · NOC 38110 · Supplement to a New Drug Submission (SNDS)
- PMS-ENZALUTAMIDEAugust 14, 2026 · NOC 38124 · Abbreviated New Drug Submission (ANDS)
- PMS-AZITHROMYCINAugust 7, 2026 · NOC 38071 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-ESOMEPRAZOLE DRAugust 5, 2026 · NOC 38049 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-TOFACITINIBJuly 30, 2026 · NOC 38017 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-NIFEDIPINE ERJuly 21, 2026 · NOC 37955 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-VILAZODONEMay 29, 2026 · NOC 37637 · Abbreviated New Drug Submission (ANDS)
- PMS-DULOXETINEMay 29, 2026 · NOC 37647 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-ZOPICLONEMay 21, 2026 · NOC 37584 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-SALBUTAMOLMay 19, 2026 · NOC 37572 · Supplement to a New Drug Submission (SNDS)
- PMSC-ESOMEPRAZOLE DRMay 15, 2026 · NOC 37552 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-PROGESTERONEMay 15, 2026 · NOC 37563 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-SUMATRIPTANMay 7, 2026 · NOC 37492 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-GABAPENTINApril 27, 2026 · NOC 37402 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-TOFACITINIBApril 24, 2026 · NOC 37405 · Supplement to an Abbreviated New Drug Submission (SANDS)
- ACID CONTROLLER MAXIMUM STRENGTHApril 17, 2026 · NOC 37343 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-IRBESARTANApril 15, 2026 · NOC 37333 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-DOLUTEGRAVIRApril 14, 2026 · NOC 37332 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-DOLUTEGRAVIRApril 14, 2026 · NOC 37335 · Abbreviated New Drug Submission (ANDS)
- PMS-CITALOPRAMApril 1, 2026 · NOC 37246 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-DEXTROAMPHETAMINEMarch 10, 2026 · NOC 37075 · Abbreviated New Drug Submission (ANDS)
- PRAXIS ASA EC 81 MG DAILY LOW DOSEMarch 6, 2026 · NOC 37049 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-RIVAROXABANFebruary 25, 2026 · NOC 36977 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-BOSENTANFebruary 25, 2026 · NOC 36978 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-VALPROIC ACID; PMS-VALPROIC ACID E.C.February 23, 2026 · NOC 36958 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-IRBESARTAN-HCTZFebruary 19, 2026 · NOC 36935 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-TOPIRAMATEFebruary 9, 2026 · NOC 36858 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-NILOTINIBFebruary 2, 2026 · NOC 36816 · Abbreviated New Drug Submission (ANDS)
- PMS-ATENOLOLJanuary 16, 2026 · NOC 36744 · Supplement to a New Drug Submission (SNDS)
- PMS-SACUBITRIL-VALSARTANJanuary 13, 2026 · NOC 36729 · Abbreviated New Drug Submission (ANDS)
- PMS-METRONIDAZOLE GELJanuary 2, 2026 · NOC 36665 · New Drug Submission (NDS)
- PMS-SUGAMMADEXDecember 12, 2025 · NOC 36535 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-FINGOLIMODDecember 11, 2025 · NOC 36529 · Supplement to an Abbreviated New Drug Submission (SANDS)
- OLESTYRDecember 9, 2025 · NOC 36505 · Supplement to a New Drug Submission (SNDS)
- PMS-EDOXABANNovember 26, 2025 · NOC 36431 · Abbreviated New Drug Submission (ANDS)
- PMSC-VENLAFAXINE XRNovember 10, 2025 · NOC 36345 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-GABAPENTINOctober 31, 2025 · NOC 36321 · Supplement to an Abbreviated New Drug Submission (SANDS)
- GLATECTOctober 29, 2025 · NOC 36278 · Supplement to a New Drug Submission (SNDS)
- PMS-LEVODOPA-CARBIDOPAOctober 16, 2025 · NOC 36195 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-LAMOTRIGINEOctober 16, 2025 · NOC 36196 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-METHOTREXATE TABLETSOctober 14, 2025 · NOC 36159 · Abbreviated New Drug Submission (ANDS)
- PMS-TELMISARTANOctober 10, 2025 · NOC 36150 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-BILASTINEOctober 2, 2025 · NOC 36103 · Abbreviated New Drug Submission (ANDS)
- FLUOXETINE CAPSULESSeptember 23, 2025 · NOC 36048 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-PALBOCICLIBSeptember 5, 2025 · NOC 36065 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-AZITHROMYCINAugust 28, 2025 · NOC 35922 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-ALENDRONATE-FCAugust 18, 2025 · NOC 35854 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-ALENDRONATEAugust 18, 2025 · NOC 35855 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-OXYCODONEAugust 7, 2025 · NOC 35937 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMSC-NIFEDIPINE ERJuly 25, 2025 · NOC 35743 · Abbreviated New Drug Submission (ANDS)
- ALLERGY RELIEF; EXTRA STRENGTH ALLERGY RELIEFJuly 24, 2025 · NOC 35727 · Supplement to an Abbreviated New Drug Submission (SANDS)
- ASA DAILY LOW DOSEJune 17, 2025 · NOC 35543 · Supplement to a New Drug Submission (SNDS)
- PMS-TERAZOSINJune 10, 2025 · NOC 35505 · Supplement to an Abbreviated New Drug Submission (SANDS)
- ASA 81 MGMay 23, 2025 · NOC 35404 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-PRAVASTATINMay 16, 2025 · NOC 35369 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-DONEPEZILMay 15, 2025 · NOC 35360 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-IVERMECTINMay 1, 2025 · NOC 35283 · New Drug Submission (NDS)
- PMS-ROSUVASTATINApril 30, 2025 · NOC 35282 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-TERIFLUNOMIDEApril 29, 2025 · NOC 35269 · Supplement to an Abbreviated New Drug Submission (SANDS)
- ACID CONTROLLER MAXIMUM STRENGTHApril 28, 2025 · NOC 35257 · Abbreviated New Drug Submission (ANDS)
- PMS-DAPAGLIFLOZINApril 17, 2025 · NOC 35229 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-ANASTROZOLEApril 17, 2025 · NOC 35263 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-FAMPRIDINEApril 14, 2025 · NOC 35186 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-TERBINAFINEApril 8, 2025 · NOC 35137 · Supplement to an Abbreviated New Drug Submission (SANDS)
- IBUPROFEN MUSCLE AND JOINTMarch 28, 2025 · NOC 35102 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-METHOTREXATE INJECTIONMarch 28, 2025 · NOC 35123 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-PALBOCICLIBMarch 21, 2025 · NOC 35053 · Supplement to an Abbreviated New Drug Submission (SANDS)
- ANALGESIC AND MUSCLE RELAXANTMarch 7, 2025 · NOC 34967 · Supplement to a New Drug Submission (SNDS)
- PMS-CETIRIZINEMarch 7, 2025 · NOC 34972 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-ANASTROZOLEMarch 7, 2025 · NOC 34974 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-BETAHISTINEMarch 5, 2025 · NOC 34955 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-DOXYCYCLINEFebruary 27, 2025 · NOC 34921 · New Drug Submission (NDS)
- PMS-ZOPICLONEFebruary 21, 2025 · NOC 34902 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-BOSENTANFebruary 19, 2025 · NOC 34875 · Supplement to an Abbreviated New Drug Submission (SANDS)
- NAPROXEN MENSTRUAL PAIN RELIEFJanuary 29, 2025 · NOC 34769 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-PREDNISOLONEJanuary 24, 2025 · NOC 34735 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-RUPATADINEJanuary 21, 2025 · NOC 34712 · Abbreviated New Drug Submission (ANDS)
- PMS-METHOTREXATEJanuary 8, 2025 · NOC 34643 · Supplement to a New Drug Submission (SNDS)
- PMS-VALPROIC ACID; PMS-VALPROIC ACID E.C.January 8, 2025 · NOC 34648 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-FLUCONAZOLEDecember 18, 2024 · NOC 34578 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-ESCITALOPRAMDecember 9, 2024 · NOC 34535 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-LETROZOLEDecember 5, 2024 · NOC 34495 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-LAMOTRIGINENovember 28, 2024 · NOC 34462 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-TOFACITINIBNovember 28, 2024 · NOC 34469 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-CYTARABINENovember 27, 2024 · NOC 34454 · Supplement to a New Drug Submission (SNDS)
- PMS-RIVAROXABANNovember 4, 2024 · NOC 34327 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-NAPROXENOctober 28, 2024 · NOC 34289 · Supplement to a New Drug Submission (SNDS)
- PMSC-ESOMEPRAZOLE DROctober 21, 2024 · NOC 34241 · Supplement to an Abbreviated New Drug Submission (SANDS)
- DIARRHEA RELIEFOctober 18, 2024 · NOC 34261 · Supplement to a New Drug Submission (SNDS)
- EXTRA STRENGTH IBUPROFEN; IBUPROFEN CAPLETS; IBUPROFEN TABLETSOctober 18, 2024 · NOC 34275 · Supplement to an Abbreviated New Drug Submission (SANDS)
- PMS-BICALUTAMIDEOctober 11, 2024 · NOC 34201 · Supplement to an Abbreviated New Drug Submission (SANDS)
The latest 100 of 1,224.
Recalls and safety alerts that mention its products
Health Canada’s recall notices do not carry licence numbers, so these are matched by name. A notice may cover another product or only some lots: read it to see what it covers.
- PMS-Carvedilol 25 mg Tablets: Out-of-specification (Impurity)October 6, 2026 · Drugs · Product quality · Type II
- PMS-FAMPRIDINE 10 mg Tablet: Affected lot may contain foreign material particles.October 6, 2026 · Drugs · Contamination · Type II
- pms-IRBESARTAN: Affected lot may contain pms-IRBESARTAN/HCTZ 150/12.5 mg tablets.August 12, 2026 · Drugs · Contamination · Type II
- PMS-Fluconazole 50 mg tablets; Incorrect quantity of tabletsJune 8, 2026 · Drugs · Packaging · Type III
- PMS-BUSULFAN 6mg/mL: impurity could be out of specificationApril 29, 2026 · Drugs · Product quality · Type III
- Moxifloxacin : assay out of trendMarch 30, 2026 · Drugs · Product quality · Type II
- PMS-Zolpidem ODT 10mg: Missing tablets in blister packsDecember 3, 2025 · Drugs · Packaging · Type II
- PMS-QUETIAPINE: Out of SpecificationNovember 20, 2025 · Drugs · Product quality · Type III
- PMS-Busulfan 6 mg/mL; Out of specification (Impurities)September 2, 2025 · Drugs · Product quality · Type III
- PMS-SUMATRIPTAN: may not contain the correct amount of tablets (empty blister packs)August 29, 2025 · Drugs · Product quality · Type II
- PMS-Methylphenidate CR 10 mg capsule; exceed the acceptable intake limit for N-nitroso-methylphenidateJuly 4, 2025 · Drugs · Product quality · Type I
- PMS-Fluoxetine 10 mg capsule; may exceed the interim acceptable intake limit for N-nitroso-fluoxetineJune 30, 2025 · Drugs · Product quality · Type I
- Accel-Ondansetron ODT, Mint-Betahistine and PMS-Pirfenidone tablets recalled due to data integrity concernsJune 17, 2025 · Drugs · Product safety
- PMS-FLUOXETINE: Affected lots exceed the interim acceptable intake limit for N-nitroso-fluoxetine.April 28, 2025 · Drugs · Product quality · Type I
- PMS-FLUOXETINE 10 mg - May contain capsules of PMS-Fluoxetine 20mg.January 31, 2025 · Drugs · Product quality · Type II
- PMS-CINACALCET: Affected lots may exceed the established acceptable intake limit for N-nitroso-cinacalcet.December 30, 2024 · Drugs · Product safety · Type I
- PMS-PREGABALIN: Affected lot may contain empty capsules.November 14, 2024 · Drugs · Product quality - Product safety · Type II
- PMS-PIRFENIDONE 267 & 801 mg: Data integrity concerns with products bioequivalence data that could lead to incorrect dosing.June 7, 2024 · Drugs · Product quality · Type I
- PMS-Duloxetine 60 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)April 17, 2024 · Drugs · Product quality · Type I
- PMS-Duloxetine 30 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)April 17, 2024 · Drugs · Product quality · Type I
- PMS-Perindopril: Defective sealsDecember 15, 2023 · Drugs · Packaging · Type II
- PMS-AMITRIPTYLINE 10 mg, 25 mg, and 50 mg: NDMA and NNORT impurityAugust 16, 2023 · Drugs · Contamination · Type I
- PMS-Montelukast: An impurity is out of trendAugust 9, 2023 · Drugs · Product quality · Type II
- Rhinaris Nasal Mist: One lot recalled due to risk of microbial growth which may lead to infectionJuly 7, 2023 · Drugs · Product safety
- Rhinaris Nasal Mist: Out of specification - Antimicrobial EffectivenessJune 30, 2023 · Drugs · Product quality · Type II
- PMS-Pazopanib 200 mg tablet; Presence of SorafenibMay 31, 2023 · Drugs · Product quality · Type II
- PMS-Hydromorphone: Affected lot may contain tablets that could potentially lead to overdoseAugust 22, 2022 · Drugs · Adverse reaction - Dosage - Labelling - Packaging - Product safety - Product withdrawal · Type I
- Recall of one lot of pms-Hydromorphone due to packaging error that could potentially lead to overdoseAugust 20, 2022 · Drugs · Adverse reaction - Dosage - Labelling - Packaging - Product safety - Product withdrawal
- PMS-Montelukast: impurityMay 19, 2022 · Drugs · Product quality · Type II
- Pharmascience PMS-Losartan product recall (2021-10-13)October 13, 2021 · Drugs · Product safety · Type I
- PMS-Montelukast (2021-08-30)August 30, 2021 · Drugs · Product safety · Type II
- One lot of pms-PROGESTERONE 100 mg capsules recalled because it may pose serious risks to individuals with severe peanut allergiesAugust 24, 2021 · Drugs
- PMS-PROGESTERONE (2021-08-20)August 20, 2021 · Drugs · Product safety · Type I
- PMS-RABEPRAZOLE EC(2021-06-18)June 18, 2021 · Drugs · Product safety · Type II
- PMS-Irbesartan/HCTZ Product Recall (2021-05-25)May 25, 2021 · Drugs · Product safety · Type I
- PMS-Irbesartan Product Recall (2021-05-25)May 25, 2021 · Drugs · Product safety · Type I
- Rhinaris Nasal Mist (2021-03-22)March 22, 2021 · Drugs · Product safety · Type II
- PMS-Ranitidine 150mg(2021-02-04)February 4, 2021 · Drugs · Product safety · Type I
- PMS-Docusate Sodium(2021-01-26)January 26, 2021 · Drugs · Product safety · Type II
- PMS-Pregabalin 150mg(2020-01-15)January 15, 2021 · Drugs · Product safety · Type II
- Rhinaris Nasal Mist (2020-12-15)December 15, 2020 · Drugs · Product safety · Type II
- PMS-Pregabalin 50mg (2020-12-14)December 14, 2020 · Drugs · Product safety · Type II
- Rhinaris Nasal Spray (2020-11-19)November 19, 2020 · Drugs · Product safety · Type II
- pms-Ranitidine 150mg (2020-08-28)August 28, 2020 · Drugs · Product safety · Type I
- PMS-Sildenafil R (2020-06-02)June 2, 2020 · Drugs · Product safety · Type II
- PMS-Zolmitriptan ODT (2020-02-26)February 26, 2020 · Drugs · Product safety · Type II
- PMS-Nystatin Suspension (2020-01-13)January 13, 2020 · Drugs · Product safety · Type II
- PMS-Galantamine ER (2019-10-22)October 22, 2019 · Drugs · Product safety · Type II
- PMS-Galantamine ER (2019-06-25)June 25, 2019 · Drugs · Product safety · Type II
- PMS-Galantamine ER (2019-06-19)June 19, 2019 · Drugs · Product safety · Type II
- PMS-Cetirizine tablets (2019-04-26)April 26, 2019 · Drugs · Product safety · Type III
- PMS-Sulfasalazine product recall (2019-04-09)April 9, 2019 · Drugs · Product safety · Type III
- PMS-Amoxicillin (2019-03-11)March 11, 2019 · Drugs · Product safety · Type III
- Updated - PMS-Lactulose Syrup (2019-02-07)February 7, 2019 · Drugs · Product safety · Type III
- PMS-Lactulose Syrup (2019-01-22)January 22, 2019 · Drugs · Product safety · Type III
- PMS-Amoxicillin (2018-12-03)December 3, 2018 · Drugs · Product safety · Type III
- PMS-Solifenacin 5mg Tablet (2018-10-03)October 3, 2018 · Drugs · Product safety · Type II
- PMS-Ciprofloxacin 250mg Tablet (2018-08-08)August 8, 2018 · Drugs · Product safety · Type II
- pms-Méthylphénidate ER (2017-10-10)October 19, 2017 · Drugs · Product safety · Type II
- Serophene Tab 50mg (2017-07-17)October 4, 2017 · Drugs · Product safety · Type III
- PMS-Diclofenac (2017-07-17)October 4, 2017 · Drugs · Product safety · Type III
- pms-Bisacodyl (2017-09-15)October 3, 2017 · Drugs · Product safety · Type III
- PMS-AMLODIPINE (2017-03-28)April 10, 2017 · Drugs · Product safety · Type II
- PMS-PRAVASTATIN (2017-03-28)April 10, 2017 · Drugs · Product safety · Type II
- pms-Omeprazole (2016-09-06)September 20, 2016 · Drugs · Product safety · Type II
- pms-Clonazepam (2016-09-06)September 20, 2016 · Drugs · Product safety · Type II
- pms-SULFASALAZINE E.C. (2016-08-04)August 10, 2016 · Drugs · Product safety · Type II
- pms-Atenolol (2016-08-04)August 9, 2016 · Drugs · Product safety · Type I
- pms-Atenolol (2016-07-19)July 27, 2016 · Drugs · Product safety · Type II
- pms-Pramipexole (2016-07-19)July 25, 2016 · Drugs · Product safety · Type II
- pms-Betahistine (2016-05-12)May 24, 2016 · Drugs · Product safety · Type II
- pms-Zopiclone (2015-09-24)October 6, 2015 · Drugs · Product safety · Type II
- PMS-Enalapril Product Recall (2015-04-29)May 7, 2015 · Drugs · Product safety · Type II
- PMS-Olanzapine (2015-02-18)February 26, 2015 · Drugs · Product safety · Type II
- PMS-Rosuvastatin (2014-12-31)January 8, 2015 · Drugs · Product safety · Type II
- PMS-Amlodipine-Atorvastatin (2014-12-31)January 8, 2015 · Drugs · Product safety · Type II
- Serophene (2014-08-26)September 2, 2014 · Drugs · Product safety · Type II
- PMS-Losartan-HCTZ (2014-05-23)May 28, 2014 · Drugs · Product safety · Type I
- Hypertension drug PMS-Losartan-HCTZ recalled due to labelling errorMay 23, 2014 · Drugs · Labelling
- pms-Pantoprazole (2014-04-01)April 8, 2014 · Drugs · Product safety · Type II
- pms-Simvastatin (2013-10-16)November 6, 2013 · Drugs · Product safety · Type II
- PMS-PravastatinApril 23, 2013 · Drugs · Product safety · Type II
- Archived – Pms-Phenobarbital (60 mg) Being Recalled in Canada due to Risk of Accidental OverdoseJune 26, 2009 · Drugs · Dosage